DRD2 and neoplasm: These data suggest that in NF-PitNETs, DRD2 can reduce cell proliferation by both the β-arrestin 2 and the G-protein-mediated pathways, depending on the tumor, and that in tumors resistant to all DRD2 ligands, alterations common to the two pathways may be present.